Needham & Company Reiterates Strong Buy Rating on Myriad Genetics (MYGN) as Final LCD Issued for myPath Melanoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/16/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. WDAY
8. ADYEN:NA
9. DVLT
10. ADYYF

Go back to Needham & Company Reiterates Strong Buy Rating on Myriad Genetics (MYGN) as Final LCD Issued for myPath Melanoma

Myriad’s myPath® Melanoma Test Receives Medicare Coverage

March 14, 2019 8:02 AM EDT

SALT LAKE CITY, March 14, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that the Medicare Administrative Contractor Palmetto GBA MolDx has issued a final local coverage determination (LCD) for the... More